Nippon Chemiphar Sees Profits Halved

Sales Drop 4% Due To Japanese NHI Drug Price Revisions

Japanese NHI drug price revisions implemented in October 2019 are responsible for operating profits halving amid declining sales and future uncertainty, Nippon Chemiphar said as it slashed its full-year forecast.

Graph_Sales_Decrease
The firm’s declining sales and profits have led it to slash its forecasts • Source: Shutterstock

Japan’s Nippon Chemiphar saw its operating profit more than halved and a 4% drop in year-on-year generics sales in the first nine months of its financial year ending 31 March 2020, as the company said it was “unable to compensate for the impact of National Health Insurance drug price revisions implemented in October 2019.”

Nippon Chemiphar reported generics sales down by 4% to ¥20.61bn ($187m) for the first nine months of the financial year,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business